Every material Form 8-K Aligos Therapeutics, Inc. has filed with the SEC since June 26, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Aligos Therapeutics reported third quarter 2026 results on November 6, 2026, with a net loss of $21.9 million, down from $31.5 million a year earlier, as revenue rose and research and development spending fell to $18.9 million. Cash, cash equivalents and investments of $31.1 million are expected to fund planned operations only into the first quarter of 2027.
Net loss for the three months ended September 30, 2026 was $21.9 million, or $(2.09) per share, versus $31.5 million, or $(3.04) per share, a year earlier.
Revenue from customers was $2.8 million, up from $0.7 million, and licensing revenue was $39 thousand, compared with none in the prior-year quarter.
Cash, cash equivalents and investments totaled $31.1 million at September 30, 2026, down from $77.8 million at December 31, 2025.
Topline data from the Phase 2 B-SUPREME study of pevifoscorvir sodium are expected in late Q3 2027.
Aligos Therapeutics amended the lease for its South San Francisco headquarters, extending the term from March 31, 2027 to March 31, 2034. The amendment sets rising monthly base rent per square foot, grants a ten-month rent abatement, and gives the company an option to terminate in 2031 for a $2,476,429.22 fee.
Lease term extended from March 31, 2027 to March 31, 2034, with base rent of $4.650 to $5.716 per rentable square foot per month
Ten-month rent abatement from April 1, 2027 to January 31, 2028, if there is no material default
One-time option to terminate as of March 31, 2031, with notice by March 31, 2030 and $2,476,429.22 termination consideration
Aligos Therapeutics reported its second quarter 2026 results on August 6, 2026. The net loss narrowed sharply from $15.9 million a year earlier, helped by $27.8 million in licensing revenue tied to its Greater China deal with Amoytop, while research and development spending rose. Cash and investments fell to $30.4 million, and the company says that cash will fund planned operations only through the fourth quarter of 2026.
Q2 2026 net loss was $1.5 million, or $(0.14) per share, versus a net loss of $15.9 million, or $(1.53) per share, in Q2 2025.
Licensing revenue was $27.8 million in Q2 2026, compared with no licensing revenue in Q2 2025.
R&D expenses rose to $24.1 million from $14.0 million, mainly due to third-party costs for the pevifoscorvir sodium Phase 2 trial.
Cash, cash equivalents and investments were $30.4 million at June 30, 2026, down from $77.8 million at December 31, 2025, and exclude a $25 million upfront payment received in July 2026.
At its June 25, 2026 Annual Meeting, Aligos Therapeutics stockholders approved an amendment to the 2020 Employee Stock Purchase Plan that reserves 500,000 additional shares and removes the plan's automatic annual share-reserve increases through 2030. Stockholders also elected two Class III directors, ratified Ernst & Young LLP as auditor for 2026, and backed an annual frequency for future advisory pay votes.
ESPP amendment reserves 500,000 additional shares and eliminates the evergreen provision, so the reserve will be fixed with no further automatic increases.
Proposal 3 (ESPP amendment) received 2,161,966 votes for, 17,797 against, 1,108 abstentions and 1,613,003 broker non-votes.
Bridget Martell and Carole Nuechterlein were elected as Class III directors, with 2,092,164 and 2,086,481 votes for, respectively.
The Company will hold advisory say-on-pay votes annually, following 2,077,884 stockholder votes for a one-year frequency.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Aligos Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →